

Substitute for form 1449A/PTO

**INFORMATION
DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete in 15 min

RECEIVED
MAY 16 2001
TECH CENTER 1600/2900

U.S. PATENT & TRADEMARK OFFICE
MAY 14 2001

Application Number	09/689,430
Filing Date	10/12/00
First Named Inventor	Walsh, et al.
Group Art Unit	1642
Examiner Name	To be Assigned
Attorney Docket Number	5052-53

Sheet 1 of 1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document Number	Kind Code ² (if known)	Name of Patentee or Applicant Of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Office ³	Number ⁴	Kind Code (if known) ⁵	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
JL	22		WO 97/45550	✓	ZHANG, W.	12-04-1997		
JL	23		WO 98/09524	✓	SRIVASTAVA, A.	03-12-1998		
JL	24		WO 99/61642	✓	SNYDER, R.	12-02-1999		
JL	25		WO 00/23116	✓	COUTO, L.	04-27-2000		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
JL	26	CHAO, H., et al., Sustained Expression of Human Factor VIII in Mice Using a Parvovirus-Based Vector (2000) Blood, Vol. 95(5), pp. 1594-1599	
JL	27 ✓	ILL, C., et al., Optimization of the Human Factor VIII Complementary DNA Expression Plasmid for Gene Therapy of Hemophilia A (1997) Blood Coagulation & Fibrinolysis, Vol. 8(2), pp. S23-S30	
JL	28	Wang, L., et al., Sustained Correction of Bleeding Disorder in Hemophilia B Mice by Gene Therapy (1999) Proc. Natl. Acad. Sci. USA Vol. 96, pp. 3906-3910	
Examiner Signature	D. J. L.		Date Considered 11/19/01

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RTA01/2095839v1

¹ Unique citation designation number.

² See attached Kinds of U.S. Patent Documents.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.

⁶ Applicant is to place an "X" here if English language Translation is attached.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT



(Use as many sheets as necessary)

Sheet 2 of 2

Application Number	09/689,443
Filing Date	October 12, 2000
First Named Inventor	Walsh <i>et al.</i>
Group Art Unit	1642
Examiner Name	Not Assigned
Attorney Docket Number	35052/204373(5052-53)

RECEIVED
APR 13 2001
Technology Center 2100

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	13	CONNELLY <i>et al.</i> , "Complete Short-Term Correction of Canine Hemophilia A by In Vivo Gene Therapy," <i>Blood</i> , November 15, 1996, Vol. 88, No. 10, pp. 3846-3853	
	14 ✓	CONNELLY <i>et al.</i> , "Sustained Phenotypic Correction of Murine Hemophilia A by In Vivo Gene Therapy," <i>Blood</i> , May 1, 1998, Vol. 91, No. 9, pp. 3273-3281	
	15 ✓	DONG <i>et al.</i> , "Quantitative Analysis of the Packaging Capacity of Recombinant Adeno-Associated Virus," <i>Human Gene Therapy</i> , November 10, 1996, Vol. 7, pp. 2111-2112	
	16 ✓	DWARKI <i>et al.</i> , "Gene Therapy for Hemophilia A: Production of Therapeutic Levels of Human Factor VIII in Vivo in Mice," <i>Proc. Natl. Acad. Sci. USA</i> , February 1995, Vol. 92, pp. 1023-1027	
	17 ✓	GNATENKO <i>et al.</i> , "Human Factor VIII can be Packaged and Functionally Expressed in an Adeno-Associated Virus Background: Applicability to Haemophilia A Gene Therapy," <i>British Journal of Haematology</i> , 1999, Vol. 104, pp. 27-36	
	18 ✓	HERZOG <i>et al.</i> , "Problems and Prospects in Gene Therapy for Hemophilia," <i>Current Opinion in Hematology</i> , 1998, pp. 321-326	
	19 ✓	KAY <i>et al.</i> , "In Vivo Gene Therapy of Hemophilia B: Sustained Partial Correction in Factor IX-Deficient Dogs," <i>Science</i> , October 1, 1993, Vol. 262, pp. 117-119	
	20 ✓	LOZIER <i>et al.</i> , "Gene Therapy and the Hemophilias," <i>JAMA</i> , January 5, 1994, Vol. 271, No. 1, Pp. 47-51	
	21 ✓	RUSSELL <i>et al.</i> , "Adeno-Associated Virus Vectors and Hematology," <i>Blood</i> , August 1, 1999, Vol. 94, No. 3, pp. 864-874	

RTA01/2093596v1

Examiner Signature		Date Considered	11/19/01
--------------------	---	-----------------	----------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

APR 02 2001
PATENT & TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Application Number 09/689,433
 Filing Date October 12, 2000
 First Named Inventor Walsh *et al.*
 Group Art Unit 1642
 Examiner Name Not Assigned
 Attorney Docket Number 35052/204373(5052-53)

RECEIVED
 APR 13 2001
 Technology Center 2100

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant Of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear
		Number	Kind Code (if known)			
J	1	5,750,172		Meade <i>et al.</i>	05-12-1998	
	2	5,843,742		Natsoulis <i>et al.</i>	12-01-1998	
	3	5,856,152		Wilson <i>et al.</i>	01-05-1999	
	4	5,858,775		Johnson	01-12-1999	
	5	5,866,696		Carter <i>et al.</i>	02-02-1999	
	6	5,871,986		Boyce	02-16-1999	
	7	5,880,327		Lubon <i>et al.</i>	03-09-1999	
	8	5,885,971		German <i>et al.</i>	03-23-1999	
	9	6,200,560		Couto <i>et al.</i>	03-13-2001	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
J	10	BARTLETT <i>et al.</i> , "Genetics and Biology of Adeno-Associated Virus," <i>Viral Vectors, Gene Therapy and Neuroscience Applications</i> (1995), pp. 55-73, Edited by Kaplitt and Loewy, Academic Press, Inc.	
J	11 ✓	CHUAH <i>et al.</i> , "Gene Therapy for Hemophilia: Hopes and Hurdles," <i>Critical Reviews in Oncology/Hematology</i> (1998) Vol. 28, pp. 153-171	
J	12 ✓	CONNELLY <i>et al.</i> , "Sustained Expression of Therapeutic Levels of Human Factor VIII in Mice," <i>Blood</i> , June 1, 1996, Vol. 87, No. 11, pp. 4671-4677	

Examiner Signature	<i>D. James L.</i>	Date Considered	11/19/01
-----------------------	--------------------	--------------------	----------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.